Toll Free: 1-888-928-9744

Small-Cell Lung Cancer - Pipeline Review, H1 2016

Published: May 25, 2016 | Pages: 645 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Small-Cell Lung Cancer - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Small-Cell Lung Cancer - Pipeline Review, H1 2016', provides an overview of the Small-Cell Lung Cancer pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer
- The report reviews pipeline therapeutics for Small-Cell Lung Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Small-Cell Lung Cancer therapeutics and enlists all their major and minor projects
- The report assesses Small-Cell Lung Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 7 Small-Cell Lung Cancer Overview 8 Therapeutics Development 9 Small-Cell Lung Cancer - Therapeutics under Development by Companies 11 Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes 16 Small-Cell Lung Cancer - Pipeline Products Glance 17 Small-Cell Lung Cancer - Products under Development by Companies 20 Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes 27 Small-Cell Lung Cancer - Companies Involved in Therapeutics Development 28 Small-Cell Lung Cancer - Therapeutics Assessment 100 Drug Profiles 122 Small-Cell Lung Cancer - Recent Pipeline Updates 372 Small-Cell Lung Cancer - Dormant Projects 614 Small-Cell Lung Cancer - Discontinued Products 621 Small-Cell Lung Cancer - Product Development Milestones 623 Appendix 631
List of Tables
Number of Products under Development for Small-Cell Lung Cancer, H1 2016 22 Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2016 23 Number of Products under Development by Companies, H1 2016 24 Number of Products under Development by Companies, H1 2016 (Contd..1) 25 Number of Products under Development by Companies, H1 2016 (Contd..2) 26 Number of Products under Development by Companies, H1 2016 (Contd..3) 27 Number of Products under Development by Companies, H1 2016 (Contd..4) 28 Number of Products under Investigation by Universities/Institutes, H1 2016 29 Comparative Analysis by Late Stage Development, H1 2016 30 Comparative Analysis by Clinical Stage Development, H1 2016 31 Comparative Analysis by Early Stage Development, H1 2016 32 Products under Development by Companies, H1 2016 33 Products under Development by Companies, H1 2016 (Contd..1) 34 Products under Development by Companies, H1 2016 (Contd..2) 35 Products under Development by Companies, H1 2016 (Contd..3) 36 Products under Development by Companies, H1 2016 (Contd..4) 37 Products under Development by Companies, H1 2016 (Contd..5) 38 Products under Development by Companies, H1 2016 (Contd..6) 39 Products under Investigation by Universities/Institutes, H1 2016 40 Small-Cell Lung Cancer - Pipeline by 4SC AG, H1 2016 41 Small-Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2016 42 Small-Cell Lung Cancer - Pipeline by AbbVie Inc., H1 2016 43 Small-Cell Lung Cancer - Pipeline by Alchemia Limited, H1 2016 44 Small-Cell Lung Cancer - Pipeline by Amgen Inc., H1 2016 45 Small-Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals, Inc., H1 2016 46 Small-Cell Lung Cancer - Pipeline by Aposense Ltd., H1 2016 47 Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc., H1 2016 48 Small-Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2016 49 Small-Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 50 Small-Cell Lung Cancer - Pipeline by Bayer AG, H1 2016 51 Small-Cell Lung Cancer - Pipeline by BeiGene, Ltd., H1 2016 52 Small-Cell Lung Cancer - Pipeline by BIND Therapeutics, Inc., H1 2016 53 Small-Cell Lung Cancer - Pipeline by BioLineRx, Ltd., H1 2016 54 Small-Cell Lung Cancer - Pipeline by Bionomics Limited, H1 2016 55 Small-Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 56 Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 57 Small-Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H1 2016 58 Small-Cell Lung Cancer - Pipeline by Cellceutix Corporation, H1 2016 59 Small-Cell Lung Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016 60 Small-Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 61 Small-Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016 62 Small-Cell Lung Cancer - Pipeline by CytRx Corporation, H1 2016 63 Small-Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2016 64 Small-Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2016 65 Small-Cell Lung Cancer - Pipeline by Exelixis, Inc., H1 2016 66 Small-Cell Lung Cancer - Pipeline by G1 Therapeutics, Inc., H1 2016 67 Small-Cell Lung Cancer - Pipeline by Genzyme Corporation, H1 2016 68 Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016 69 Small-Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H1 2016 70 Small-Cell Lung Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016 71 Small-Cell Lung Cancer - Pipeline by Immunomedics, Inc., H1 2016 72 Small-Cell Lung Cancer - Pipeline by Incyte Corporation, H1 2016 73 Small-Cell Lung Cancer - Pipeline by Ipsen S.A., H1 2016 74 Small-Cell Lung Cancer - Pipeline by Johnson & Johnson, H1 2016 75 Small-Cell Lung Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 76 Small-Cell Lung Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 77 Small-Cell Lung Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 78 Small-Cell Lung Cancer - Pipeline by Lindis Biotech GmbH, H1 2016 79 Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016 80 Small-Cell Lung Cancer - Pipeline by MedImmune, LLC, H1 2016 81 Small-Cell Lung Cancer - Pipeline by Medivation, Inc., H1 2016 82 Small-Cell Lung Cancer - Pipeline by MEI Pharma, Inc., H1 2016 83 Small-Cell Lung Cancer - Pipeline by Merck & Co., Inc., H1 2016 84 Small-Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 85 Small-Cell Lung Cancer - Pipeline by Mirna Therapeutics, Inc., H1 2016 86 Small-Cell Lung Cancer - Pipeline by MolMed S.p.A., H1 2016 87 Small-Cell Lung Cancer - Pipeline by Mologen AG, H1 2016 88 Small-Cell Lung Cancer - Pipeline by NanoSmart Pharmaceuticals, Inc., H1 2016 89 Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H1 2016 90 Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2016 91 Small-Cell Lung Cancer - Pipeline by Novartis AG, H1 2016 92 Small-Cell Lung Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016 93 Small-Cell Lung Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 94 Small-Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 95 Small-Cell Lung Cancer - Pipeline by Onxeo SA, H1 2016 96 Small-Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H1 2016 97 Small-Cell Lung Cancer - Pipeline by Pfizer Inc., H1 2016 98 Small-Cell Lung Cancer - Pipeline by Pharma Mar, S.A., H1 2016 99 Small-Cell Lung Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 100 Small-Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016 101 Small-Cell Lung Cancer - Pipeline by SciTech Development, LLC , H1 2016 102 Small-Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 103 Small-Cell Lung Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 104 Small-Cell Lung Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 105 Small-Cell Lung Cancer - Pipeline by Syros Pharmaceuticals, Inc., H1 2016 106 Small-Cell Lung Cancer - Pipeline by Tarveda Therapeutics, Inc., H1 2016 107 Small-Cell Lung Cancer - Pipeline by Tesaro, Inc., H1 2016 108 Small-Cell Lung Cancer - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 109 Small-Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 110 Small-Cell Lung Cancer - Pipeline by ViiV Healthcare Limited, H1 2016 111 Small-Cell Lung Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016 112 Assessment by Monotherapy Products, H1 2016 113 Assessment by Combination Products, H1 2016 114 Number of Products by Stage and Target, H1 2016 116 Number of Products by Stage and Mechanism of Action, H1 2016 125 Number of Products by Stage and Route of Administration, H1 2016 132 Number of Products by Stage and Molecule Type, H1 2016 134 Small-Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H1 2016 385 Small-Cell Lung Cancer - Dormant Projects, H1 2016 627 Small-Cell Lung Cancer - Dormant Projects (Contd..1), H1 2016 628 Small-Cell Lung Cancer - Dormant Projects (Contd..2), H1 2016 629 Small-Cell Lung Cancer - Dormant Projects (Contd..3), H1 2016 630 Small-Cell Lung Cancer - Dormant Projects (Contd..4), H1 2016 631 Small-Cell Lung Cancer - Dormant Projects (Contd..5), H1 2016 632 Small-Cell Lung Cancer - Dormant Projects (Contd..6), H1 2016 633 Small-Cell Lung Cancer - Discontinued Products, H1 2016 634 Small-Cell Lung Cancer - Discontinued Products (Contd..1), H1 2016 635


List of Figures
Number of Products under Development for Small-Cell Lung Cancer, H1 2016 22 Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2016 23 Number of Products under Development by Companies, H1 2016 24 Number of Products under Investigation by Universities/Institutes, H1 2016 29 Comparative Analysis by Late Stage Development, H1 2016 30 Comparative Analysis by Clinical Stage Development, H1 2016 31 Comparative Analysis by Early Stage Products, H1 2016 32 Assessment by Monotherapy Products, H1 2016 113 Assessment by Combination Products, H1 2016 114 Number of Products by Top 10 Targets, H1 2016 115 Number of Products by Stage and Top 10 Targets, H1 2016 115 Number of Products by Top 10 Mechanism of Actions, H1 2016 124 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 124 Number of Products by Routes of Administration, H1 2016 131 Number of Products by Stage and Routes of Administration, H1 2016 131 Number of Products by Top 10 Molecule Types, H1 2016 133 Number of Products by Stage and Top 10 Molecule Types, H1 2016 133

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the dem

Read More...

Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive t

Read More...

Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliab

Read More...

Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance driv

Read More...

Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demand

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify